Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
Sathe N, Shaikh S, Bhavsar M, Parte L, Gadiparthi A, Kad S, Sensarma S, Nalband H, Sangapillai R, Sivashanmuganathan S, Pusalkar R, Anandan S, Masand G, Pratapreddy K, Harinarayana Rao S, Gokhale A, Vidyadhar Reddy GEC, Karanam G, Phatarphekar A, Rao P, Ramana V, Ramnath RL.
Sathe N, et al.
Vaccine. 2024 Feb 15;42(5):1051-1064. doi: 10.1016/j.vaccine.2023.10.006. Epub 2023 Oct 8.
Vaccine. 2024.
PMID: 37816655